GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

For media and investors onlyData from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIbViiV Healthcare, the global... Read More
GSK
3 years ago ⋅ English ⋅ 2 min read
Newsroom
GSK regulatory submission accepted by Japanese regulator for respiratory syncytial virus older adult vaccine candidate

For media and investors only- Regulatory submission based on positive pivotal phase III data showing vaccine efficacy against respiratory syncytial virus-lower respiratory tract disease... Read More
GSK
3 years ago ⋅ English ⋅ 7 min read
Newsroom
New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over

For media and investors only- Overall, the clinical benefit was sustained through the current follow-up period of up to 10 years after vaccination in adults aged 50 years and over- In t... Read More
GSK
3 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D

GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&DFor media and investors only- Collaboration leverages one of world’s largest sources of... Read More
GSK
3 years ago ⋅ English ⋅ 3 min read
Newsroom
US FDA approves Menveo in a new single-vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y, and W

For media and investors onlySingle-vial presentation option removes the need for reconstitution of Menveo before use in individuals 10 through 55 years of age.GSK plc (LSE/NYSE: GSK) to... Read More
GSK
3 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

For media and investors onlyData to be presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, wit... Read More